Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancer

Expert Opinion on Drug Discovery
Juliet E Wolford, Krishnansu S Tewari

Abstract

Though cervical cytology, HPV DNA testing, and pre-invasive disease management has significantly reduced the number of new diagnoses of cervical cancer, women with persistent oncogenic HPV infection are at significant risk for developing invasive cervical cancer. Early stage and locally advanced disease can be cured, but women with advanced or recurrent disease have a very poor prognosis. This underscores the need for different treatment strategies for advanced cervical cancer, the most promising of which are novel therapeutics that target the ability of HPV to overcome host immune tolerance. Areas covered: This review includes new therapies being investigated for the treatment of recurrent, metastatic or refractory cervical cancer, separated into broad categories of cellular and non-cellular based strategies. Expert opinion: Advanced and recurrent cervical cancer has a poor prognosis, prompting investigations into the development of strategies that will eradicate tumor and/or overcome host immunologic tolerance of disease. It is unknown whether it will be these strategies alone or a combination of treatment modalities that will ultimately provide the best outcomes; nevertheless, the new data are promising.

References

Jun 5, 2002·Nature Reviews. Cancer·Harald zur Hausen
Feb 7, 2003·The New England Journal of Medicine·Nubia MuñozUNKNOWN International Agency for Research on Cancer Multicenter Cervical Cancer Study Group
Jul 4, 2007·International Immunology·Taku Okazaki, Tasuku Honjo
Jul 25, 2009·Nature Reviews. Cancer·Jeffrey A Engelman
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Oct 19, 2010·The Lancet Oncology·Silvia de SanjoseUNKNOWN Retrospective International Survey and HPV Time Trends Study Group
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Apr 5, 2013·Cancer Research·Judith MichelsGuido Kroemer
Oct 8, 2013·Frontiers in Oncology·Raquel E Reinbolt, John L Hays
Feb 21, 2014·The New England Journal of Medicine·Krishnansu S TewariBradley J Monk
Sep 19, 2014·World Journal of Gastrointestinal Oncology·Víctor M Castellano-MegíasFrancisco Colina-Ruizdelgado
Oct 12, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Curtis R PickeringMitchell J Frederick
Dec 11, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michaela K KeckTanguy Y Seiwert
Jan 17, 2015·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Charles KunosKathleen N Moore
Jan 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael A PostowJedd D Wolchok
Feb 13, 2015·Biomedical Journal·Ya-Shan Chen, Chia-Rui Shen
Apr 1, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sanja StevanovićChristian S Hinrichs
Apr 8, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Emese ZsirosKunle Odunsi
Sep 26, 2015·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Louisa MezacheGerard J Nuovo
Apr 3, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christian S Hinrichs
Apr 9, 2016·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·A Marijne HeerenEkaterina S Jordanova
Oct 11, 2016·The New England Journal of Medicine·Robert L FerrisMaura L Gillison
Dec 22, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P H ThakerP M Fracasso
Dec 29, 2016·Journal of Gynecologic Oncology·Valerie HeongDavid Shao Peng Tan
Apr 20, 2017·Genome Medicine·Zachary R ChalmersGarrett M Frampton
Jun 8, 2017·Gynecologic Oncology Research and Practice·Brett A MilesHoward P Safran
Jul 21, 2017·Gynecologic Oncology Research and Practice·Brett MilesBradley J Monk
Oct 12, 2017·The New England Journal of Medicine·Steven LemeryRichard Pazdur
Jan 10, 2018·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations

Apr 27, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Krishnansu S Tewari
Mar 24, 2020·Cell Death and Differentiation·Sang Ah YiSo Hee Kwon
Aug 14, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Krishnansu S Tewari, Bradley J Monk
Jul 31, 2020·Signal Transduction and Targeted Therapy·Qiao WangXia Zhao
Aug 6, 2021·Frontiers in Cell and Developmental Biology·Hongjuan SongLiping Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Drug Design, Development and Therapy
Thanashan Rajakulendran, David N Adam
Surgical Oncology Clinics of North America
J W Orr
Cytopathology : Official Journal of the British Society for Clinical Cytology
A TalaatR Woolas
© 2022 Meta ULC. All rights reserved